X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
UBX1325 (foselutoclax) is a potent small molecule inhibitor of Bcl-xL, a member of the BCL-2 family of apoptosis regulating proteins. It is being evaluated for the treatment of diabetic macular edema.
Lead Product(s): Foselutoclax
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
UBX1325 (foselutoclax) is a potent small molecule & Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema (DME).
Lead Product(s): Foselutoclax
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
The net proceeds will be used for the advancement of UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, currently being evaluated for the treatment of age-related diseases of the eye, including diabetic macular edema.
Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 10, 2023
Details:
UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins, which is investigated for the treatment of Wet Age-Related Macular Degeneration.
Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival.
Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham treatment.
Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2022
Details:
Patients with diabetic macular edema and wet age-related macular degeneration showed improvement in visual acuity through 24 weeks following single dose of UBX1325, a potent small molecule inhibitor of Bcl-xL in Advanced vascular eye disease.
Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
UBX1325 is a potent small molecule inhibitor of Bcl-xL, being studied for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR).
Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
UBX1325, a small molecule inhibitor of Bcl-xL and the first senolytic drug candidate for ophthalmologic diseases targeting a distinctive biologic pathway from anti-VEGF therapies used in diabetic macular edema (DME) and wet age-related macular degeneration.
Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2021
Details:
UBX1325 is a small-molecule inhibitor of Bcl-xL, and the first senolytic therapeutic clinically evaluated in an ophthalmological setting. UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma.
Lead Product(s): UBX1325
Therapeutic Area: Ophthalmology Product Name: UBX1325
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Ascentage Pharma
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
